...Jun Luo; Zehui Rao; Kun Zhou; Kun Liu; Runfu Cao; Kaihong Wang Introduction: Degarelix and relugolix are two GnRH antagonists approved by the FDA for androgen deprivation therapy in the treatment of prostate cancer. However, differences in their safety profiles and the characteristics of specific...

...Yuanshan Cui; Huantao Zong; Huilei Yan; Nan Li; Yong Zhang Objective: We performed a systematic review and meta-analysis to assess the efficacy and tolerability of degarelix for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer...

...John Anderson; Ghandi Al-Ali; Manfred Wirth; Joan Benejam Gual; Francisco Gomez Veiga; Enrico Colli; Egbert van der Meulen; Bo-Eric Persson Introduction: No studies to date have assessed the efficacy/tolerability of degarelix in the relief of lower urinary tract symptoms (LUTS) secondary...